Tirzepatide

Continuing tirzepatide MTD resulted in a mean bodyweight change of -21.9% at week 112, significantly greater than 5 mg (-16.6%) and placebo (-9.9%).; Rescue tirzepatide was received by 8% of MTD, 25% of 5 mg, and 67% of placebo participants who regained at least 50% of lost bodyweight.; Gastrointestinal adverse events were the most common with tirzepatide, mostly mild to moderate and occurring during dose escalation.; Reducing to 5 mg tirzepatide may be a valuable alternative to discontinuation for maintaining weight reduction.

At Week 72, tirzepatide reduced body weight by 20.1% versus 12.9% with semaglutide (LSM difference -7.2%, 95% CI -9.3 to -5.1; p<.001).; More tirzepatide-treated participants achieved 10%, 15%, 20%, 25%, and 30% weight-loss targets.; Tirzepatide led to significantly greater reductions in waist circumference and BMI, evident from Weeks 4 and 12, respectively, and maintained through Week 72.; Safety profile was generally consistent with the overall SURMOUNT-5 population, with gastrointestinal events most common.

Tirzepatide, a dual GLP-1 and GIP receptor agonist used for weight management, can rarely cause severe metabolic complications like ketoacidosis.; This patient without diabetes developed hyperglycemic ketoacidosis, unlike two previously reported cases in patients without diabetes that involved euglycemic ketoacidosis with normal glucose levels.; Treatment with intravenous fluids, insulin infusion, and electrolyte replacement led to full recovery.; Vigilant monitoring for metabolic complications, including hyperglycemia and ketoacidosis, is important in patients without diabetes on tirzepatide, particularly those with comorbidities.

No evidence of a difference in all-cause mortality (OR 1.02, 95% CI 0.57 to 1.81; TSA underpowered; very low certainty of evidence); No evidence of a difference in serious adverse events (OR 0.98, 95% CI 0.82 to 1.17; TSA sufficiently powered; moderate certainty of evidence); Tirzepatide increased the risk of several non-serious adverse events, primarily gastrointestinal events such as nausea, diarrhea, decreased appetite, and vomiting; Further trials designed to investigate effects on all-cause mortality are needed

Semaglutide provides robust cardiovascular protection in obesity management.; Tirzepatide produces greater weight loss and broad metabolic benefits.; Mechanistic differences, tolerability, and real-world factors such as patient access and sustainability are relevant to clinical decision-making.; Both agents support reconceptualizing obesity as a chronic disease requiring ongoing pharmacological management.

Tirzepatide dominated semaglutide, yielding greater health benefits at lower costs.; Tirzepatide's ICER versus diet and exercise was $57,400 per QALY.; RYGB provided greater benefits at lower costs than both GLP1RAs and had a $30,700 per QALY ICER versus LSG.; At a $100,000 per QALY threshold, tirzepatide had a 64% and semaglutide a 34% probability of being cost-effective.

Tirzepatide significantly reduced HbA1c by 2.23% compared with placebo at 30 weeks (p<0.0001).; BMI reductions were 7.4% (5 mg) and 11.2% (10 mg) versus 0.4% with placebo at 30 weeks.; Glycaemic efficacy was sustained up to 52 weeks with tirzepatide treatment.; Most common adverse events were gastrointestinal, mild to moderate in severity, with no deaths reported.

Average predicted 10-year CVD risk score before treatment was 9.3%.; Tirzepatide showed a greater absolute reduction in predicted 10-year CVD risk than semaglutide (2.4% vs 1.4%, P < 0.001).; An estimated 2 million CVD events could potentially be prevented over 10 years with tirzepatide versus 1.15 million with semaglutide in the eligible US population (~85 million).; The analysis suggests tirzepatide may provide greater benefit in primary prevention of CVD than semaglutide in people with obesity and overweight.

What is Tirzepatide?

**Mechanism of Action** Tirzepatide is a synthetic peptide that functions as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique co-agonism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, delays gastri

How does Tirzepatide work?

Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.

What is the research status of Tirzepatide?

Tirzepatide is currently classified as approved, with 2,668 research references on record. This is for research purposes only and is not medical advice.

What is the half-life of Tirzepatide?

The reported half-life of Tirzepatide is ~5 days.

What is the molecular weight of Tirzepatide?

Tirzepatide has a molecular weight of approximately 4813 g/mol (formula C225H348N48O68).